Latest News

Novartis launches COPD inhalers in China



NovartisNovartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease.

The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide. Seebri Breezhaler is a fixed-dose formulation of glycopyrronium bromide.

Get the full story at our sister site, Drug Delivery Business News.

The post Novartis launches COPD inhalers in China appeared first on MassDevice.

Source link




Related posts

Aptar Enters into Strategic Partnership with PureCycle to Accelerate Integration of Ultra-Pure Recycled Polypropylene into Dispensing Solutions

Newsemia

Faulty Immune System May Lead to Lung Cancer

Newsemia

Tufts to review ties to Purdue Pharma after ‘deeply troubling’ disclosures

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy